全文获取类型
收费全文 | 2390篇 |
免费 | 104篇 |
国内免费 | 106篇 |
专业分类
2600篇 |
出版年
2024年 | 10篇 |
2023年 | 145篇 |
2022年 | 357篇 |
2021年 | 545篇 |
2020年 | 227篇 |
2019年 | 77篇 |
2018年 | 50篇 |
2017年 | 30篇 |
2016年 | 33篇 |
2015年 | 26篇 |
2014年 | 68篇 |
2013年 | 103篇 |
2012年 | 46篇 |
2011年 | 68篇 |
2010年 | 44篇 |
2009年 | 65篇 |
2008年 | 59篇 |
2007年 | 85篇 |
2006年 | 52篇 |
2005年 | 57篇 |
2004年 | 48篇 |
2003年 | 59篇 |
2002年 | 36篇 |
2001年 | 28篇 |
2000年 | 14篇 |
1999年 | 29篇 |
1998年 | 24篇 |
1997年 | 18篇 |
1996年 | 6篇 |
1995年 | 14篇 |
1994年 | 9篇 |
1993年 | 11篇 |
1992年 | 10篇 |
1991年 | 12篇 |
1990年 | 8篇 |
1989年 | 4篇 |
1988年 | 10篇 |
1987年 | 5篇 |
1986年 | 4篇 |
1985年 | 9篇 |
1984年 | 12篇 |
1983年 | 6篇 |
1982年 | 9篇 |
1981年 | 12篇 |
1980年 | 14篇 |
1979年 | 6篇 |
1978年 | 7篇 |
1977年 | 11篇 |
1976年 | 6篇 |
1975年 | 5篇 |
排序方式: 共有2600条查询结果,搜索用时 15 毫秒
91.
Singh Ashutosh Singh Rahul Soloman Sarma Phulen Batra Gitika Joshi Rupa Kaur Hardeep Sharma Amit Raj Prakash Ajay Medhi Bikash 《中国病毒学》2020,35(3):290-304
The recent outbreak of coronavirus disease(COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) has already affected a large population of the world. SARS-CoV-2 belongs to the same family of severe acute respiratory syndrome coronavirus(SARS-CoV) and Middle East respiratory syndrome coronavirus(MERSCoV). COVID-19 has a complex pathology involving severe acute respiratory infection, hyper-immune response, and coagulopathy. At present, there is no therapeutic drug or vaccine approved for the disease. There is an urgent need for an ideal animal model that can reflect clinical symptoms and underlying etiopathogenesis similar to COVID-19 patients which can be further used for evaluation of underlying mechanisms, potential vaccines, and therapeutic strategies. The current review provides a paramount insight into the available animal models of SARS-CoV-2, SARS-CoV, and MERS-CoV for the management of the diseases. 相似文献
92.
Virologica Sinica - Coronavirus disease 2019 (COVID-19), reminiscent of the severe acute respiratory syndrome (SARS) outbreak in 2003, has been a tragic disaster to people all over the world. As... 相似文献
93.
Tian Suyan Zhu Xuetong Sun Xuejuan Wang Jinmei Zhou Qi Wang Chi Chen Li Li Shanji Xu Jiancheng 《中国病毒学》2020,35(6):811-819
Virologica Sinica - The temporal change patterns of laboratory data may provide insightful clues into the whole course of COVID-19. This study aimed to evaluate longitudinal change patterns of key... 相似文献
94.
Kong Wen-Hua Zhao Rong Zhou Jun-Bo Wang Fang Kong De-Guang Sun Jian-Bin Ruan Qiong-Fang Liu Man-Qing 《中国病毒学》2020,35(6):752-757
Virologica Sinica - The immense patient number caused by coronavirus disease 2019 (COVID-19) global pandemic brings the urge for more knowledge about its immunological features, including the... 相似文献
95.
《Reports of Practical Oncology and Radiotherapy》2020,25(5):765-767
AimTo provide recommendations for the management of patients with cancer in the COVID-19 era.BackgroundThe current global pandemic of COVID-19 has severely impacted global healthcare systems. Several groups of people are considered high-risk for SARS-CoV-2 infection, including patients with cancer. Therefore, protocols for the better management of these patients during this viral pandemic are necessary. So far, several protocols have been presented regarding the management of patients with cancer during the COVID-19 pandemic. However, none of them points to a developing country with limited logistics and facilities.MethodsIn this review, we have provided a summary of recommendations on the management of patients with cancer during the COVID-19 pandemic based on our experience in Shohada-e Tajrish Hospital, Iran.ResultsWe recommend that patients with cancer should be managed in an individualized manner during the COVID-19 pandemic.ConclusionsOur recommendation provides a guide for oncology centers of developing countries for better management of cancer. 相似文献
96.
《Revista iberoamericana de micología》2020,37(2):41-46
Critically ill COVID-19 patients have higher pro-inflammatory (IL-1, IL-2, IL-6, tumor necrosis alpha) and anti-inflammatory (IL-4, IL-10) cytokine levels, less CD4 interferon-gamma expression, and fewer CD4 and CD8 cells. This severe clinical situation increases the risk of serious fungal infections, such as invasive pulmonary aspergillosis, invasive candidiasis or Pneumocystis jirovecii pneumonia. However, few studies have investigated fungal coinfections in this population. We describe an update on published reports on fungal coinfections and our personal experience in three Spanish hospitals. We can conclude that despite the serious disease caused by SARS-CoV-2 in many patients, the scarcity of invasive mycoses is probably due to the few bronchoscopies and necropsies performed in these patients because of the high risk in aerosol generation. However, the presence of fungal markers in clinically relevant specimens, with the exception of bronchopulmonary colonization by Candida, should make it advisable to early implement antifungal therapy. 相似文献
97.
《Microbes and infection / Institut Pasteur》2020,22(4-5):212-217
Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) is continuously and rapidly circulating at present. Asymptomatic patients have been proven to be contagious and thus pose a significant infection control challenge. Here we describe the characteristics of asymptomatic patients with SARS-CoV-2 infection in Jinan, Shandong province, China. A total of 47 patients with confirmed COVID-19 were recruited. Among them, 11 patients were categorized as asymptomatic cases. We found that the asymptomatic patients in Jinan were relatively young and were mainly clustered cases. The laboratory indicators and lung lesion on chest CT were mild. No special factors were found accounting for the presence or absence of symptoms. The presence of asymptomatic patients increased the difficulty of screening. It is necessary to strengthen the identification of such patients in the future. 相似文献
98.
《Microbes and infection / Institut Pasteur》2020,22(4-5):200-205
The spread of COVID-19 is accelerating. At present, there is no specific antiviral drugs for COVID-19 outbreak. This is a multicenter retrospective cohort study of patients with laboratory-confirmed COVID-19 infection pneumonia from 3 hospitals in Hubei and Guangdong province, 141 adults (aged ≥18 years) without ventilation were included. Combined group patients were given Arbidol and IFN-α2b, monotherapy group patients inhaled IFN-α2b for 10–14 days. Of 141 COVID-19 patients, baseline clinical and laboratory characteristics were similar between combined group and monotherapy group, that 30% of the patients leucocytes counts were below the normal range and 36.4% of the patients experienced lymphocytopenia. The duration of viral RNA of respiratory tract in the monotherapy group was not longer than that in the combined therapy group. There was no significant differences between two groups. The absorption of pneumonia in the combined group was faster than that in the monotherapy group. We inferred that Arbidol/IFN - 2 b therapy can be used as an effective method to improve the COVID-19 pneumonia of mild patients, although it helpless with accelerating the virus clearance. These results should be verified in a larger prospective randomized environment. 相似文献
99.
100.
Duarte Gouveia Lucia Grenga Jean‐Charles Gaillard Fabrice Gallais Laurent Bellanger Olivier Pible Jean Armengaud 《Proteomics》2020,20(14)
Detection of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a crucial tool for fighting the COVID‐19 pandemic. This dataset brief presents the exploration of a shotgun proteomics dataset acquired on SARS‐CoV‐2 infected Vero cells. Proteins from inactivated virus samples were extracted, digested with trypsin, and the resulting peptides were identified by data‐dependent acquisition tandem mass spectrometry. The 101 peptides reporting for six viral proteins were specifically analyzed in terms of their analytical characteristics, species specificity and conservation, and their proneness to structural modifications. Based on these results, a shortlist of 14 peptides from the N, S, and M main structural proteins that could be used for targeted mass‐spectrometry method development and diagnostic of the new SARS‐CoV‐2 is proposed and the best candidates are commented. 相似文献